Waverley Pharma (TSXV:WAVE) Common Stock : C$7.00 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Waverley Pharma Common Stock?

Waverley Pharma's quarterly common stock stayed the same from Jun. 2023 (C$7.00 Mil) to Sep. 2023 (C$7.00 Mil) and stayed the same from Sep. 2023 (C$7.00 Mil) to Dec. 2023 (C$7.00 Mil).

Waverley Pharma's annual common stock stayed the same from Dec. 2021 (C$7.00 Mil) to Dec. 2022 (C$7.00 Mil) and stayed the same from Dec. 2022 (C$7.00 Mil) to Dec. 2023 (C$7.00 Mil).

Waverley Pharma Common Stock Historical Data

The historical data trend for Waverley Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waverley Pharma Common Stock Chart

Waverley Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

7.00

Waverley Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															7.00	7.00	7.00	7.00	7.00

Waverley Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Waverley Pharma (TSXV:WAVE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (TSXV:WAVE) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

5GZ:Germany

Address

1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6

Website

https://www.waverleypharma.com

Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.